Usage pattern, glycemic improvement, hypoglycemia, and body mass index changes with sulfonylureas in real-life clinical practice: Results from OBSTACLE hypoglycemia study

Diabetes Technology and Therapeutics

Volumn 15, Issue 2, 2013, Pages 129-135

  Kalra, Sanjay ^a   Deepak, M C ^b   Narang, Prashant ^c   Singh, Vikram ^d   Uvaraj, M G ^e   Agrawal, Navneet ^f  

^a India   (India)

^b Madhav Diabetes Center   (India)

^c MSD Pharmaceuticals Pvt Ltd   (India)

^d MSD (Pty) Ltd   (South Africa)

^e MG Diabetes Speciality and Research Centre   (India)

^f Diabetes Obesity and Thyroid Centre   (India)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BODY MASS; CLINICAL PRACTICE; CORRELATION ANALYSIS; DRUG EFFECT; DRUG USE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INDIA; MALE; MEDICAL RECORDS; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; QUESTIONNAIRES; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84873179268     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2012.0237     Document Type: Article

References (15)

1. Whiting DR, Guariguata L, Weil C, Shaw J: IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-321
2. Mohan V, Madan Z, Jha R, Deepa R, Pradeepa R: Diabetes - social and economic perspectives in the new millenium. Int J Diabetes Dev Ctries 2004;24:29-35
3. Zimmet P: The burden of type 2 diabetes: Are we doing enough? Diabetes Metab 2003;29:6S9-6S18
4. Guidelines for Management of Type 2 Diabetes. http:// icmr.nic.in/guidelines-diabetes/section7.pdf (May 28, 2012
5. Sultana G, Kapur P, Aqil M, Alam MS, Pillai KK: Drug utilization of oral hypoglycemic agents in a university teaching hospital in India. J Clin Pharmacol Ther 2010;35:267-277
6. Garg A, Akhtar MS, Rana A, Abida, Parvez N: A comparative study between retrospective and prospective drug use pattern conducted in a referral teaching hospital, New Delhi, India. IJPI J Hosp Clin Pharm 2012;2(8). www.ijpi journals.com/Articles/PDF/280.pdf (December 18, 2012
7. Ramesh R, Kumar SV, Gopinath S, Gavaskar B, Gandhiji G: Diabetic knowledge of rural community and drug utilization pattern in a tertiary care hospital. Int J Pharm Life Sci 2011; 2:531-535
8. Hasamnis AA, Patil SS: Prescription pattern study in type 2 diabetes mellitus in an Indian referral hospital. www.ispub .com/journal/the-internet- journal-of-pharmacology/volume-7-number-1/prescription-pattern-study-in-Type-2- Diabetesmellitus-in-An-indian-referral-hospital.html#sthash.hclBpSw7 .dpbs (October 17, 2012
9. Sutharson L, Hariharan RS, Vamsadhara C: Drug utilization study in diabetology outpatient setting of a tertiary hospital. Indian J Pharmacol 2003;35:237-240
10. Del Prato S, Pulizzi N: The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism 2006; 55(5 SUPPL1):S20-S27
11. Melander A: Kinetics-Effect relations of insulin-releasing drugs in patients with type 2 diabetes: Brief overview. Diabetes 2004;53(SUPPL3):S151- S155
12. Campbell IW: Sulfonylureas and hypoglycaemia. Diabet Hypoglycemia 2009;2:3-10
13. Purnell JQ, Weyer C: Weight effect of current and experimental drugs for diabetes mellitus: From promotion to alleviation of obesity. Treat Endocrinol 2003;2: 33-47
14. Cryer PE: Hypoglycemia: The limiting factor in the glycemic management of type I and type II diabetes. Diabetologia 2002;45:937-948
15. Amiel SA, Dixon T, Mann R, Jameson K: Hypoglycaemia in Type 2 diabetes. Diabet Med 2008;25:245-254